What is Amphastar Pharmaceuticals's primatenemist — revenue?

Amphastar Pharmaceuticals (AMPH) reported primatenemist — revenue of $0 in Q2 2026.

What does primatenemist — revenue mean?

This metric represents the total gross sales generated from the Primatenemist product line, net of returns, allowances, and discounts. It serves as a key indicator of market demand and commercial adoption for this specific therapeutic offering within the company's portfolio. Tracking these revenues helps investors assess the product's contribution to overall top-line growth and its competitive positioning in the respiratory or injectable market.

Amphastar Pharmaceuticals (AMPH) Primatenemist — Revenue

Screener

Other product segments

Baqsimi

$13.84M—

Similar metrics at other companies

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

AEPCommercial Revenues — Revenue

$1.21B+15.4%

EQIXRecurring revenues — Revenue

$2.38B+10.9%

GCTProduct revenues — Revenue

$290.82M+28.9%

Other financials

Income statement

See full

Revenue$183.9M+5.4%

Gross profit$93.5M+8.1%

Operating income$39.7M-5.8%

Net income$30.3M-2.2%

EPS (diluted)$0.67+4.7%

Balance sheet

See full

Cash & equivalents$223.6M+19.1%

Total debt$688.5M+5.0%

Total equity$445.5M—

Total assets$1.7B+8.0%

Cash flow

See full

Operating cash flow$51.3M+44.2%

CapEx$8.6M-18.7%

Free cash flow$42.7M+70.7%

Valuation

See full

Market cap$916.25M-28.0%

Enterprise value$1.38B-20.6%

P/E11.7×+2.2×

P/S1.3×-0.5×

Profitability

See full

Gross margin47.7%-2.2pp

Operating margin15.7%-9.5pp

Net margin10.8%-7.9pp

FCF margin20.9%+5.4pp

Returns & leverage

See full

Return on equity14.7%—

Debt / equity0.2×—

Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:50 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001297184-26-000047

Line item	Three Months Ended / June 30, 2026	Three Months Ended / June 30, 2025	Six Months Ended / June 30, 2026	Six Months Ended / June 30, 2025
Net revenues	$183,903	$174,414	$355,074	$344,942
Cost of revenues	90,433	87,924	191,282	173,201
Gross profit	93,470	86,490	163,792	171,741
Operating expenses:
Selling, distribution, and marketing	13,335	10,235	25,262	22,101
General and administrative	18,242	13,991	36,270	29,987
Research and development	22,164	20,080	48,901	40,176
Total operating expenses	53,741	44,306	110,433	92,264

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's primatenemist — revenue?: Amphastar Pharmaceuticals (AMPH) reported primatenemist — revenue of $0 in Q2 2026.
What does primatenemist — revenue mean?: This metric represents the total gross sales generated from the Primatenemist product line, net of returns, allowances, and discounts. It serves as a key indicator of market demand and commercial adoption for this specific therapeutic offering within the company's portfolio. Tracking these revenues helps investors assess the product's contribution to overall top-line growth and its competitive positioning in the respiratory or injectable market.